
MDAI Stock Forecast & Price Target
MDAI Analyst Ratings
Bulls say
Spectral AI is a promising company with a positive outlook due to its focus on a large and under-penetrated market, the potential for recurring revenue through its licensing model, and strong clinical performance in studies. The recent funding from BARDA further solidifies the company's financial position and its progress towards commercialization. Risks to consider include competition, limited reimbursement, and potential setbacks in regulatory and clinical timelines. Overall, Spectral AI has the potential to become a successful and stable growth company in the AI and MedTech space.
Bears say
Spectral AI is a company focused on medical diagnostics using AI, however their financials show a declining trend in profitability with increasing expenses and a reliance on government contracts for revenue, leading to a risky investment outlook. Their recent FDA clearance for the DeepView System for burn centers, trauma centers, and emergency departments is a positive milestone, but it remains to be seen if they can successfully commercialize the product and drive sustained revenue growth.
This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares